This page allows you to manage all your electronic subscriptions on this site.

Suscribe to the AREVA dashboard give you an access to newsletters, news, and email alerts from the Dialogue section...

FR EN DE

Open

AREVA Med

AREVA Med is a pioneering AREVA subsidiary that develops new methods for producing medical-grade ²¹²Pb, a promising isotope for combating cancer and other diseases. Recognized by the Clinton Global Initiative in 2009, the company is committed to supporting the search for innovative new treatments.

About AREVA Med

Based in the United States, AREVA Med is helping advance nuclear medicine by producing lead-212 on an industrial scale.

Fighting disease with lead-212

This rare radioactive isotope is at the heart of promising research in nuclear medicine to develop new cancer treatments.

Contact us

For more information about AREVA Med, please contact:

Alison Bedford
Tel.: + 1 (301) 841-1673
email: alison.bedford@areva.com

News

More news

10/20/2011

AREVA Med acquires Macrocyclics, Inc.

08/08/2011

AREVA Med initiates Phase I Clinical Trial of anti-cancer treatment with lead-212

07/12/2011

AREVA Med initiates Phase I Clinical Trial of anti-cancer treatment with lead-212

Clinical trial update

Currently recruiting patients for our Phase I study with ²¹²Pb-TCMC-Trastuzumab for HER-2 positive intra-abdominal cancers

Macrocyclics Acquisition

On October 20, 2011, Macrocyclics became part of AREVA Med. Discover our new range of products and services.

Macrocyclics Website

AREVA's U.S. Blog

Read our latest postings about AREVA Med on the US AREVA blog.

Discover the blog

MEDIA COVERAGE

02/10/2011 - TF1 : It is an unexpected specialty. AREVA, the global leader in nuclear energy, has launched a battle against cancer.

See report